CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma

Biochem Biophys Res Commun. 2004 May 7;317(3):837-43. doi: 10.1016/j.bbrc.2004.03.128.

Abstract

Immunotoxins are a potentially powerful approach for targeted anticancer therapy. We evaluated a novel immunotherapeutic strategy targeting the immunoglobulin superfamily member carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6). Using pancreatic adenocarcinoma as a model, we show that crosslinking CEACAM6 induces its cytoplasmic accumulation and that this effect can be utilized to increase the efficacy of antibody-mediated delivery of the ribosomal inhibitory protein saporin. Exposure of cells to anti-CEACAM6 antibody, followed by secondary saporin-conjugated immunoglobulin (IgG), induced marked cytotoxicity, via caspase-mediated apoptosis, in vitro. In an in vivo nude mouse xenograft model, this immunotherapeutic approach markedly suppressed pancreatic adenocarcinoma tumor growth and enhanced tumor apoptosis. Given the prevalence of CEACAM6 overexpression among human malignancies, immunological targeting of this tumor antigen may have therapeutic applicability.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / drug therapy
  • Adenocarcinoma / enzymology
  • Adenocarcinoma / metabolism*
  • Adenocarcinoma / pathology
  • Antigens, CD
  • Antigens, Neoplasm / pharmacology*
  • Antigens, Neoplasm / therapeutic use
  • Caspase 3
  • Caspases / metabolism
  • Cell Adhesion Molecules / pharmacology*
  • Cell Adhesion Molecules / therapeutic use
  • Cell Line, Tumor
  • GPI-Linked Proteins
  • Humans
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / enzymology
  • Pancreatic Neoplasms / metabolism*
  • Pancreatic Neoplasms / pathology

Substances

  • Antigens, CD
  • Antigens, Neoplasm
  • CEACAM6 protein, human
  • Cell Adhesion Molecules
  • GPI-Linked Proteins
  • CASP3 protein, human
  • Casp3 protein, mouse
  • Caspase 3
  • Caspases